Skip to content

Effects of FASTING the brain

Effects of FASTING duration on cerebral serotonin and dopamine transporter availability in lean and obese subjects

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21776
Enrollment
20
Registered
2017-07-20
Start date
2017-03-13
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fasting Obesity

Interventions

Fasting intervention: participants will undergo [123I]FP-CIT SPECT scans on two study days, prior to one study day participants will fast for 12 hours, prior to the other study day participants will f

Sponsors

Academic Medical Center (AMC), Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Male - BMI<25kg/m2 (lean subjects) or BMI ¡Ý 30kg/m2 (obese subjects) - Age 50-75 years - Stable weight three months prior to study inclusion

Exclusion criteria

Exclusion criteria: - Use of any medication except for those related to treatment of components of the metabolic syndrome - Use of exogenous insulin, oral glucose lowering drugs, beta-blockers - Any actual medical condition except for treated hypothyroidism and the metabolic syndrome - History of any psychiatric disorder - Shift work - Irregular sleep pattern - Intensive sports (>3 h/week) - Restrained eaters - History of eating disorders (anorexia, binge eating, bulimia) - Smoking, XTC, amphetamine or cocaine abuse - Alcohol abuse (>3 units/day) - Lactose intolerance - Estimated glomerular filtration rate <60 ml/min - Contraindication to MRI scanning (claustrophobia, metal foreign objects)

Design outcomes

Primary

MeasureTime frame
Serotonin and dopamine transporter availability: [123I]FP-CIT SPECT scan

Secondary

MeasureTime frame
- Circulating hormones and substrates: venous blood drawing - REE: indirect calorimetry - Feeding behavior: validated questionnaires

Contacts

Public ContactK.A. van Galen
k.a.vangalen@amc.uva.nl020-56663507

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)